ArticleOncoimmunology2021

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade.

Stefan Warmuth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.